Algestone acetophenide

Algestone acetophenide, also known more commonly as dihydroxyprogesterone acetophenide (DHPA) and sold under the brand names Perlutal and Topasel among others, is a progestin medication which is used in combination with an estrogen as a form of long-lasting injectable birth control. It has also been used alone, but is no longer available as a standalone medication. DHPA is not active by mouth and is given once a month by injection into muscle. Side effects of DHPA are similar to those of other progestins. DHPA is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has no other important hormonal activity. DHPA was discovered in 1958 and was introduced for medical use in the 1960s. It was not introduced in the United States, but it is marketed widely throughout Latin America. It was also previously available alone in Italy and as a combined injectable contraceptive in Portugal and Spain, but has been discontinued in these countries. DHPA is used in combination with estradiol enantate (E2-EN) or estradiol benzoate butyrate (EBB) as a once-monthly combined injectable contraceptive for women in Latin America, Hong Kong, and Singapore. It was also previously marketed for use alone in Italy. DHPA has reportedly been used to treat acne. E2-EN/DHPA has been said to be used by transgender women in some places of South America as feminizing hormone therapy . Estradiol enantate/algestone acetophenide and Estradiol benzoate butyrate/algestone acetophenide The following forms of DHPA in combination with an estrogen are or have been available for use: 150 mg DHPA and 10 mg estradiol enantate (brand names Perlutal, Topasel, many others) 75 mg DHPA and 5 mg estradiol enantate (brand names Anafertin, Patector NF, Yectames) 120 mg DHPA and 10 mg estradiol enantate (brand names Unalmes, Yectuna) 75 mg DHPA and 10 mg estradiol enantate (brand name Ova Repos; discontinued) 150 mg DHPA and 10 mg estradiol benzoate butyrate (brand names Neolutin N, Redimen, Soluna, Unijab) A 90 mg DHPA and 6 mg estradiol enantate formulation was also studied, but was never marketed.